NZ754961A - Growth differentiation factor 15 (gdf-15) constructs - Google Patents

Growth differentiation factor 15 (gdf-15) constructs

Info

Publication number
NZ754961A
NZ754961A NZ754961A NZ75496114A NZ754961A NZ 754961 A NZ754961 A NZ 754961A NZ 754961 A NZ754961 A NZ 754961A NZ 75496114 A NZ75496114 A NZ 75496114A NZ 754961 A NZ754961 A NZ 754961A
Authority
NZ
New Zealand
Prior art keywords
gdf15
constructs
gdf
differentiation factor
growth differentiation
Prior art date
Application number
NZ754961A
Other languages
English (en)
Inventor
Zhulun Wang
Yumei Xiong
Yi Zhang
Jackie SHENG
Agnes Hamburger
Murielle Veniant-Ellison
Grant Shimamoto
Xiaoshan Min
Jie Tang
Gunasekaran Kannan
Marissa Mock
Kenneth Walker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ754961(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NZ754961A publication Critical patent/NZ754961A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ754961A 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs NZ754961A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361860723P 2013-07-31 2013-07-31
NZ717030A NZ717030A (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs

Publications (1)

Publication Number Publication Date
NZ754961A true NZ754961A (en) 2022-04-29

Family

ID=51358091

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ717030A NZ717030A (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs
NZ754961A NZ754961A (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ717030A NZ717030A (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs

Country Status (35)

Country Link
US (4) US9862752B2 (enExample)
EP (2) EP3027642B1 (enExample)
JP (5) JP6509852B2 (enExample)
KR (3) KR20240000642A (enExample)
CN (2) CN113527512A (enExample)
AP (1) AP2016009011A0 (enExample)
AR (1) AR097181A1 (enExample)
AU (1) AU2014296107B2 (enExample)
BR (1) BR112016002213A2 (enExample)
CA (1) CA2918624C (enExample)
CL (1) CL2016000249A1 (enExample)
CR (1) CR20160097A (enExample)
CY (1) CY1123836T1 (enExample)
DK (1) DK3027642T3 (enExample)
EA (2) EA037355B1 (enExample)
ES (1) ES2828670T3 (enExample)
HU (1) HUE050630T2 (enExample)
IL (1) IL243749B (enExample)
JO (1) JO3566B1 (enExample)
LT (1) LT3027642T (enExample)
MA (1) MA38873B1 (enExample)
MX (2) MX387211B (enExample)
NZ (2) NZ717030A (enExample)
PE (1) PE20160189A1 (enExample)
PH (1) PH12016500208A1 (enExample)
PL (1) PL3027642T3 (enExample)
PT (1) PT3027642T (enExample)
SG (1) SG11201600713RA (enExample)
SI (1) SI3027642T1 (enExample)
TN (1) TN2016000035A1 (enExample)
TW (1) TWI648401B (enExample)
UA (1) UA116665C2 (enExample)
UY (1) UY35686A (enExample)
WO (1) WO2015017710A1 (enExample)
ZA (1) ZA201600523B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
JP6509852B2 (ja) * 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
JP2015182969A (ja) * 2014-03-21 2015-10-22 四国化成工業株式会社 トリアゾールシラン化合物、該化合物の合成方法及びその利用
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
AU2017241161B2 (en) 2016-03-31 2022-05-26 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CA3025251A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and uses thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
WO2019048660A1 (en) 2017-09-10 2019-03-14 Novo Nordisk A/S MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CA3096097A1 (en) 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
MA53122A (fr) * 2018-07-13 2021-05-19 Genmab As Variants d'anticorps cd38 et leurs utilisations
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
US20230053119A1 (en) * 2019-04-23 2023-02-16 Lg Chem, Ltd. FUSION POLYPEPTIDE COMPRISING Fc REGION OF IMMUNOGLOBULIN AND GDF15
AU2020283890A1 (en) * 2019-05-30 2021-12-16 Amgen Inc. Engineering the hinge region to drive antibody dimerization
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
AU2020394255A1 (en) * 2019-11-26 2022-06-09 Yuhan Corporation Long-acting GDF15 fusion protein and pharmaceutical composition comprising same
MY209909A (en) * 2019-12-11 2025-08-11 Lg Chemical Ltd Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
WO2021133822A1 (en) * 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CA3172548A1 (en) * 2020-02-20 2021-08-26 Neutrolis, Inc. Basic domain-deleted dnase1-like 3 and uses thereof
BR112022017039A2 (pt) 2020-02-28 2022-11-16 Kallyope Inc Agonistas de gpr40
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN115244076B (zh) 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
WO2023048516A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
JP2025505198A (ja) 2022-02-10 2025-02-21 ノバルティス アーゲー 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114835810B (zh) * 2022-03-31 2024-01-05 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用
WO2025024658A1 (en) * 2023-07-27 2025-01-30 Binacea Pharma, Inc. Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof
JP2025082834A (ja) 2023-11-17 2025-05-29 イーライ リリー アンド カンパニー 糖尿病又は肥満の治療のための化合物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
SK9432001A3 (en) * 1999-01-07 2003-02-04 Lexigen Pharm Corp Expression and export of anti-obesity proteins as Fc fusion proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
WO2002072608A2 (en) 2001-03-09 2002-09-19 University Of Chicago POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
JP5110877B2 (ja) * 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
JP4762904B2 (ja) * 2003-11-13 2011-08-31 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン不変領域の量産方法
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
ES2555956T3 (es) 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
WO2005113585A2 (en) * 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20060034831A1 (en) * 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
CA2628928A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
CN1974601A (zh) * 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
JP2010536717A (ja) 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP2011523051A (ja) 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
CA2732449A1 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
US20120107420A1 (en) * 2008-10-31 2012-05-03 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
WO2011091078A2 (en) * 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
EP3225994A1 (en) 2010-08-26 2017-10-04 Roche Diagnostics GmbH Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
RU2604490C2 (ru) * 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
SMT201700025T1 (it) * 2011-04-13 2017-03-08 Bristol Myers Squibb Co Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PL2794905T3 (pl) * 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
CN120383672A (zh) * 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
RU2704285C2 (ru) * 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
JP6509852B2 (ja) * 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6675333B2 (ja) 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CA3025251A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and uses thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
CR20160097A (es) 2016-07-29
US10894814B2 (en) 2021-01-19
TWI648401B (zh) 2019-01-21
SG11201600713RA (en) 2016-02-26
CN105980400B (zh) 2021-05-07
SI3027642T1 (sl) 2020-11-30
MX387211B (es) 2025-03-18
IL243749A0 (en) 2016-04-21
CL2016000249A1 (es) 2016-07-22
JP6509852B2 (ja) 2019-05-08
CA2918624A1 (en) 2015-02-05
PH12016500208B1 (en) 2016-04-25
CN105980400A (zh) 2016-09-28
KR20160038896A (ko) 2016-04-07
BR112016002213A2 (pt) 2017-08-29
WO2015017710A1 (en) 2015-02-05
KR20240000642A (ko) 2024-01-02
PH12016500208A1 (en) 2016-04-25
KR20220038829A (ko) 2022-03-29
LT3027642T (lt) 2020-10-12
CA2918624C (en) 2024-02-13
MA38873A1 (fr) 2017-09-29
KR102376451B1 (ko) 2022-03-23
US20240368236A1 (en) 2024-11-07
UY35686A (es) 2015-01-30
NZ717030A (en) 2022-04-29
AU2014296107B2 (en) 2018-07-26
PT3027642T (pt) 2020-10-30
CN113527512A (zh) 2021-10-22
JP6877478B2 (ja) 2021-05-26
AP2016009011A0 (en) 2016-01-31
PE20160189A1 (es) 2016-05-06
JP2021113219A (ja) 2021-08-05
EP3027642B1 (en) 2020-08-19
MA38873B1 (fr) 2018-11-30
EA202092386A1 (ru) 2021-04-30
CY1123836T1 (el) 2022-03-24
TW201602345A (zh) 2016-01-16
DK3027642T3 (da) 2020-11-02
US20210079051A1 (en) 2021-03-18
MX2019012848A (es) 2019-11-28
US20160168213A1 (en) 2016-06-16
MX369152B (es) 2019-10-30
HUE050630T2 (hu) 2020-12-28
AU2014296107A1 (en) 2016-02-04
PL3027642T3 (pl) 2021-01-11
TN2016000035A1 (en) 2017-07-05
EP3027642A1 (en) 2016-06-08
JP2025024032A (ja) 2025-02-19
MX2016001164A (es) 2016-07-26
EA201690297A1 (ru) 2016-06-30
HK1225738A1 (en) 2017-09-15
JP2016532690A (ja) 2016-10-20
UA116665C2 (uk) 2018-04-25
ES2828670T3 (es) 2021-05-27
IL243749B (en) 2018-06-28
ZA201600523B (en) 2024-10-30
EA037355B1 (ru) 2021-03-17
JP2019178132A (ja) 2019-10-17
AR097181A1 (es) 2016-02-24
KR102616674B1 (ko) 2023-12-29
US9862752B2 (en) 2018-01-09
US20180079790A1 (en) 2018-03-22
JP2023116723A (ja) 2023-08-22
JO3566B1 (ar) 2020-07-05
EP3763734A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
NZ754961A (en) Growth differentiation factor 15 (gdf-15) constructs
Tjabringa et al. The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung
DK2480198T3 (en) STABILIZED VÆSKEFORMIGE- AND lyophilized ADAMTS13 FORMULATIONS
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
JP2014527818A (ja) Ｗｎｔ組成物およびそのような組成物の治療的使用
ES2694418T3 (es) Análogos de insulina de cadena sencilla de acción prolongada
Veldkamp et al. Solution structure of CCL19 and identification of overlapping CCR7 and PSGL-1 binding sites
MX2016005101A (es) Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
BR112020003736A2 (pt) polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais
MX373251B (es) Miméticos de calcitonina para tratar enfermedades y trastornos.
US20200054712A1 (en) Protoxin-ii variants and methods of use
ES2649862T3 (es) Sistemas y procedimientos de producción de proteínas
Křížková et al. Insulin–insulin-like growth factors hybrids as molecular probes of hormone: receptor binding specificity
NZ708091A (en) Stabilized insulin-like growth factor polypeptides
Frisch et al. Hepatocyte growth factor and alternative splice variants-expression, regulation and implications in osteogenesis and bone health and repair
CN106892975B (zh) 调节糖代谢的多肽及其用途
Jing et al. Cloning, expression and effects of P. americana thymosin on wound healing
Valls-Lacalle et al. Opposite effects of moderate and extreme Cx43 deficiency in conditional Cx43-deficient mice on angiotensin II-induced cardiac fibrosis
Pearah et al. Blocking AMPKαS496 phosphorylation improves mitochondrial dynamics and hyperglycemia in aging and obesity
JP2015536344A (ja) 外胚葉異形成症の治療のための組成物及び方法
South et al. Type VII collagen replacement therapy in recessive dystrophic epidermolysis bullosa—how much, how often?
JP2009521220A (ja) Ｂｍｐ−７変異体組成物、方法および使用
CN114096556B (zh) 表皮生长因子受体(egfr)配体
JPWO2020032076A1 (ja) 破骨細胞分化抑制剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2024 BY ANAQUA SERVICES

Effective date: 20230621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2025 BY ANAQUA SERVICES

Effective date: 20240619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2026 BY ANAQUA SERVICES

Effective date: 20250620